ABCG2 and cancer: Following exposure to varying concentrations (0-5μg/ml) of Mitoxantrone for 48h in the presence or absence of BCRP inhibitor (Ko143), the result revealed reduced cell viability in all cancer lines in the presence of Ko143 inhibitor as compared to vehicle treated (uninhibited) cells (Figures 5A–C, 5E–G).